Evidence map›Paper›PMID 28717701›Full record

ArticleJournal of global oncology2016

Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.

Glorijoy Tan, Ke Zhou, Chee Hian Tan, David B Matchar, Mohamad Farid, Richard Quek, Joanne Ngeow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Glorijoy Tan, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.
Ke Zhou, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.
Chee Hian Tan, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.
David B Matchar, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.
Mohamad Farid, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.
Richard Quek, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.
Joanne Ngeow, , , , and , National Cancer Centre Singapore; and , Tan Tock Seng Hospital; and , , , , and , Duke-National University of Singapore Graduate Medical School, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe value of screening for hepatitis B virus (HBV) infection before chemotherapy for nonhematopoietic solid tumors remains unsettled. We evaluated the cost effectiveness of universal screening before systemic therapy for sarcomas, including GI stromal tumors (GISTs). PATIENTS AND

methodsDrawing from the National Cancer Centre Singapore database of 1,039 patients with sarcomas, we analyzed the clinical records of 485 patients who received systemic therapy. Using a Markov model, we compared the cost effectiveness of a screen-all versus screen-none strategy in this population.

resultsA total of 237 patients were screened for HBV infection. No patients developed HBV reactivation during chemotherapy. The incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) of offering HBV screening to all patients with sarcomas and patients with GISTs exceeded the cost-effectiveness threshold of SG$100,000 per QALY. This result was robust in one-way sensitivity analysis. Our results show that only changes in mortality rate secondary to HBV reactivation could make the incremental cost-effectiveness ratio cross the cost-effectiveness threshold.

conclusionUniversal HBV screening in patients with sarcomas or GISTs undergoing chemotherapy is not cost effective at a willingness to pay of SG$100,000 per QALY and may not be required.

Identifiers

PMID28717701
PMCPMC5497623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.